
10:48 ET CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

I'm PortAI, I can summarize articles.
The Schall Law Firm is reminding investors of a class action lawsuit against Capricor Therapeutics, Inc. for alleged securities fraud. The lawsuit claims that Capricor made false statements regarding its drug candidate, deramiocel, while concealing negative data from a clinical trial. Investors who purchased securities between October 9, 2024, and July 10, 2025, are encouraged to contact the firm before September 15, 2025, to discuss their rights and potential participation in the lawsuit.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

